ABSTRACT
BACKGROUND: A high incidence rate of nasopharyngeal carcinoma (NPC) has been observed in Southeast Asia compared to other parts of the world. Radiomics is a computational tool to predict outcomes and may be used as a prognostic biomarker for advanced NPC treated with concurrent chemoradiotherapy. Recently, radiomic analysis of the peripheral tumor microenvironment (TME), which is the region surrounding the gross tumor volume (GTV), has shown prognostic usefulness. In this study, not only was gross tumor volume (GTVt) analyzed but also tumor peripheral regions (GTVp) were explored in terms of the TME concept. Both radiomic features and delta radiomic features were analyzed using CT images acquired in a routine radiotherapy process. METHODS: A total of 50 patients with NPC stages III, IVA, and IVB were enrolled between September 2004 and February 2014. Survival models were built using Cox regression with clinical factors (i.e., gender, age, overall stage, T stage, N stage, and treatment dose) and radiomic features. Radiomic features were extracted from GTVt and GTVp. GTVp was created surrounding GTVt for TME consideration. Furthermore, delta radiomics, which is the longitudinal change in quantitative radiomic features, was utilized for analysis. Finally, C-index values were computed using leave-one-out cross-validation (LOOCV) to evaluate the performances of all prognosis models. RESULTS: Models were built for three different clinical outcomes, including overall survival (OS), local recurrence-free survival (LRFS), and progression-free survival (PFS). The range of the C-index in clinical factor models was (0.622, 0.729). All radiomics models, including delta radiomics models, were in the range of (0.718, 0.872). Among delta radiomics models, GTVt and GTVp were in the range of (0.833, 0.872) and (0.799, 0.834), respectively. CONCLUSIONS: Radiomic analysis on the proximal region surrounding the gross tumor volume of advanced NPC patients for survival outcome evaluation was investigated, and preliminary positive results were obtained. Radiomic models and delta radiomic models demonstrated performance that was either superior to or comparable with that of conventional clinical models.
ABSTRACT
Volumetric-modulated arc therapy (VMAT) is a novel extension of the intensity-modulated radiation therapy (IMRT) technique, which has brought challenges to dose verification. To perform VMAT pretreatment quality assurance, an electronic portal imaging device (EPID) can be applied. This study's aim was to evaluate EPID performance for VMAT dose verification. First, dosimetric characteristics of EPID were investigated. Then 10 selected VMAT dose plans were measured by EPID with the rotational method. The overall variation of EPID dosimetric characteristics was within 1.4% for VMAT. The film system serving as a conventional tool for verification showed good agreement both with EPID measurements ([94.1 ± 1.5]% with 3 mm/3% criteria) and treatment planning system (TPS) calculations ([97.4 ± 2.8]% with 3 mm/3% criteria). In addition, EPID measurements for VMAT presented good agreement with TPS calculations ([99.1 ± 0.6]% with 3 mm/3% criteria). The EPID system performed the robustness of potential error findings in TPS calculations and the delivery system. This study demonstrated that an EPID system can be used as a reliable and efficient quality assurance tool for VMAT dose verification.
